Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease

Sang Moon Yun, Sun Jung Cho, Chulman Jo, Moon Ho Park, Changsu Han, Young Ho Koh

Research output: Contribution to journalArticle

Abstract

Introduction: Beta-amyloid is considered to be a pathophysiological marker in Alzheimer's disease (AD). Soluble amyloid precursor proteins (sAPPs) –α (sAPPα) and –β (sAPPβ), which are the byproducts of non-amyloidogenic and amyloidogenic process of APP, respectively, have been repeatedly observed in the cerebrospinal fluids (CSF) of AD patients. The present study focused on the determination of sAPP levels in peripheral blood. Methods: The plasma protein levels of sAPPα and sAPPβ were measured with ELISA. Plasma from 52 AD patients, 98 amnestic mild cognitive impairment (MCI) patients, and 114 cognitively normal controls were compared. Results: The plasma level of sAPPβ was significantly increased in AD patients than in cognitively healthy controls. However, no significant change in plasma sAPPα was observed among the three groups. Furthermore, the plasma sAPPβ levels significantly correlated with cognitive assessment scales, such as clinical dementia rating (CDR), and mini-mental status examination (MMSE). Interestingly, sAPPα and sAPPβ had a positive correlation with each other in blood plasma, similar to previous studies on CSF sAPP. This correlation was stronger in the MCI and AD groups than in the cognitively healthy controls. Conclusions: These results suggest that individuals with elevated plasma sAPPβ levels are at an increased risk of AD; elevation in these levels may reflect the progression of disease.

Original languageEnglish
Article number103995
JournalArchives of Gerontology and Geriatrics
Volume87
DOIs
Publication statusPublished - 2020 Mar 1

Fingerprint

Amyloid beta-Protein Precursor
Amyloid beta-Peptides
dementia
Alzheimer Disease
Cerebrospinal Fluid
Group
rating
Disease
examination
Amyloid
Dementia
Disease Progression
Blood Proteins
Enzyme-Linked Immunosorbent Assay

Keywords

  • Alzheimer's disease (AD)
  • Cognitive impairment
  • Plasma biomarker
  • Soluble amyloid precursor proteins alpha (sAPPα)
  • Soluble amyloid precursor proteins beta (sAPPβ)

ASJC Scopus subject areas

  • Health(social science)
  • Ageing
  • Gerontology
  • Geriatrics and Gerontology

Cite this

Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease. / Yun, Sang Moon; Cho, Sun Jung; Jo, Chulman; Park, Moon Ho; Han, Changsu; Koh, Young Ho.

In: Archives of Gerontology and Geriatrics, Vol. 87, 103995, 01.03.2020.

Research output: Contribution to journalArticle

@article{3c5c808c22ac4871aa729597c7da10b9,
title = "Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease",
abstract = "Introduction: Beta-amyloid is considered to be a pathophysiological marker in Alzheimer's disease (AD). Soluble amyloid precursor proteins (sAPPs) –α (sAPPα) and –β (sAPPβ), which are the byproducts of non-amyloidogenic and amyloidogenic process of APP, respectively, have been repeatedly observed in the cerebrospinal fluids (CSF) of AD patients. The present study focused on the determination of sAPP levels in peripheral blood. Methods: The plasma protein levels of sAPPα and sAPPβ were measured with ELISA. Plasma from 52 AD patients, 98 amnestic mild cognitive impairment (MCI) patients, and 114 cognitively normal controls were compared. Results: The plasma level of sAPPβ was significantly increased in AD patients than in cognitively healthy controls. However, no significant change in plasma sAPPα was observed among the three groups. Furthermore, the plasma sAPPβ levels significantly correlated with cognitive assessment scales, such as clinical dementia rating (CDR), and mini-mental status examination (MMSE). Interestingly, sAPPα and sAPPβ had a positive correlation with each other in blood plasma, similar to previous studies on CSF sAPP. This correlation was stronger in the MCI and AD groups than in the cognitively healthy controls. Conclusions: These results suggest that individuals with elevated plasma sAPPβ levels are at an increased risk of AD; elevation in these levels may reflect the progression of disease.",
keywords = "Alzheimer's disease (AD), Cognitive impairment, Plasma biomarker, Soluble amyloid precursor proteins alpha (sAPPα), Soluble amyloid precursor proteins beta (sAPPβ)",
author = "Yun, {Sang Moon} and Cho, {Sun Jung} and Chulman Jo and Park, {Moon Ho} and Changsu Han and Koh, {Young Ho}",
year = "2020",
month = "3",
day = "1",
doi = "10.1016/j.archger.2019.103995",
language = "English",
volume = "87",
journal = "Archives of Gerontology and Geriatrics",
issn = "0167-4943",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease

AU - Yun, Sang Moon

AU - Cho, Sun Jung

AU - Jo, Chulman

AU - Park, Moon Ho

AU - Han, Changsu

AU - Koh, Young Ho

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Introduction: Beta-amyloid is considered to be a pathophysiological marker in Alzheimer's disease (AD). Soluble amyloid precursor proteins (sAPPs) –α (sAPPα) and –β (sAPPβ), which are the byproducts of non-amyloidogenic and amyloidogenic process of APP, respectively, have been repeatedly observed in the cerebrospinal fluids (CSF) of AD patients. The present study focused on the determination of sAPP levels in peripheral blood. Methods: The plasma protein levels of sAPPα and sAPPβ were measured with ELISA. Plasma from 52 AD patients, 98 amnestic mild cognitive impairment (MCI) patients, and 114 cognitively normal controls were compared. Results: The plasma level of sAPPβ was significantly increased in AD patients than in cognitively healthy controls. However, no significant change in plasma sAPPα was observed among the three groups. Furthermore, the plasma sAPPβ levels significantly correlated with cognitive assessment scales, such as clinical dementia rating (CDR), and mini-mental status examination (MMSE). Interestingly, sAPPα and sAPPβ had a positive correlation with each other in blood plasma, similar to previous studies on CSF sAPP. This correlation was stronger in the MCI and AD groups than in the cognitively healthy controls. Conclusions: These results suggest that individuals with elevated plasma sAPPβ levels are at an increased risk of AD; elevation in these levels may reflect the progression of disease.

AB - Introduction: Beta-amyloid is considered to be a pathophysiological marker in Alzheimer's disease (AD). Soluble amyloid precursor proteins (sAPPs) –α (sAPPα) and –β (sAPPβ), which are the byproducts of non-amyloidogenic and amyloidogenic process of APP, respectively, have been repeatedly observed in the cerebrospinal fluids (CSF) of AD patients. The present study focused on the determination of sAPP levels in peripheral blood. Methods: The plasma protein levels of sAPPα and sAPPβ were measured with ELISA. Plasma from 52 AD patients, 98 amnestic mild cognitive impairment (MCI) patients, and 114 cognitively normal controls were compared. Results: The plasma level of sAPPβ was significantly increased in AD patients than in cognitively healthy controls. However, no significant change in plasma sAPPα was observed among the three groups. Furthermore, the plasma sAPPβ levels significantly correlated with cognitive assessment scales, such as clinical dementia rating (CDR), and mini-mental status examination (MMSE). Interestingly, sAPPα and sAPPβ had a positive correlation with each other in blood plasma, similar to previous studies on CSF sAPP. This correlation was stronger in the MCI and AD groups than in the cognitively healthy controls. Conclusions: These results suggest that individuals with elevated plasma sAPPβ levels are at an increased risk of AD; elevation in these levels may reflect the progression of disease.

KW - Alzheimer's disease (AD)

KW - Cognitive impairment

KW - Plasma biomarker

KW - Soluble amyloid precursor proteins alpha (sAPPα)

KW - Soluble amyloid precursor proteins beta (sAPPβ)

UR - http://www.scopus.com/inward/record.url?scp=85076711719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076711719&partnerID=8YFLogxK

U2 - 10.1016/j.archger.2019.103995

DO - 10.1016/j.archger.2019.103995

M3 - Article

AN - SCOPUS:85076711719

VL - 87

JO - Archives of Gerontology and Geriatrics

JF - Archives of Gerontology and Geriatrics

SN - 0167-4943

M1 - 103995

ER -